[1]韓佳妮.參芪地黃湯治療早期糖尿病腎病的療效[J].醫學信息,2019,(22):139-141.[doi:10.3969/j.issn.1006-1959.2019.22.047]
 HAN Jia-ni.Effect of Shenqi Dihuang Decoction in Treating Early Diabetic Nephropathy[J].Medical Information,2019,(22):139-141.[doi:10.3969/j.issn.1006-1959.2019.22.047]
點擊復制

參芪地黃湯治療早期糖尿病腎病的療效()
分享到:

醫學信息[ISSN:1006-1959/CN:61-1278/R]

卷:
期數:
2019年22期
頁碼:
139-141
欄目:
中醫中藥
出版日期:
2019-11-15

文章信息/Info

Title:
Effect of Shenqi Dihuang Decoction in Treating Early Diabetic Nephropathy
文章編號:
1006-1959(2019)22-0139-03
作者:
韓佳妮
(常熟市中醫院內分泌科,江蘇 常熟 215500)
Author(s):
HAN Jia-ni
(Department of Endocrinology,Changshu Traditional Chinese Medicine Hospital,Changshu 215500, Jiangsu,China)
關鍵詞:
糖尿病腎病參芪地黃湯胱抑素C尿蛋白
Keywords:
Diabetic nephropathyShenqi Dihuang DecoctionCystatin CUrine protein
分類號:
R587
DOI:
10.3969/j.issn.1006-1959.2019.22.047
文獻標志碼:
A
摘要:
目的 觀察參芪地黃湯治療早期糖尿病腎病的療效。方法 選擇2018年1月~12月我院收治的早期糖尿病腎病患者60例,按照隨機數字表法分為治療組和對照組,每組30例。兩組均進行基礎降糖降壓治療,對照組予纈沙坦治療,治療組在對照組治療基礎上加用參芪地黃湯治療,比較兩組治療前后中醫臨床證候積分、肌酐(Scr)、尿素氮(BUN)、胱抑素C(Cys-C)、24h尿蛋白定量、臨床療效及安全性情況。結果 治療后,兩組中醫臨床證候積分較治療前降低,治療組中醫臨床證候積分低于對照組,差異有統計學意義(P<0.05)。兩組Scr、BUN、24h尿蛋白定量、Cys-C較治療前降低,治療組Scr、BUN、24h尿蛋白定量、Cys-C低于對照組,差異有統計學意義(P<0.05)。治療組總有效率為86.67%,高于對照組的63.33%,差異有統計學意義(P<0.05)。結論 參芪地黃湯聯合纈沙坦相比單用纈沙坦能更有效降低早期糖尿病腎病患者Scr、BUN、Cys-C水平,減少24h尿蛋白定量,降低中醫臨床證候積分,改善臨床癥狀,療效確切。
Abstract:
Objective To observe the efficacy of Shenqi Dihuang Decoction in the treatment of early diabetic nephropathy. Methods 60 patients with early diabetic nephropathy admitted to our hospital from January to December 2018 were enrolled. The patients were divided into treatment group and control group according to the random number table method, 30 cases in each group. The two groups were treated with basal hypoglycemic and hypotensive treatment. The control group was treated with valsartan. The treatment group was treated with Shenqi Dihuang Decoction on the basis of the control group. The TCM clinical syndrome scores and serum creatinine (Scr) were compared before and after treatment, urea nitrogen (BUN), cystatin C (Cys-C), 24h urine protein quantification, clinical efficacy and safety. Results After treatment, the scores of TCM clinical syndromes in the two groups were lower than those before treatment. The scores of TCM clinical syndromes in the treatment group were lower than those in the control group,the difference was statistically significant (P<0.05). The Scr, BUN, 24h urine protein and Cys-C were lower than those before treatment. The Scr, BUN, 24h urine protein and Cys-C in the treatment group were lower than the control group, the difference was statistically significant (P<0.05). The total effective rate of the treatment group was 86.67%, which was higher than that of the control group 63.33%,the difference was statistically significant (P<0.05). Conclusion Shenqi Dihuang Decoction combined with valsartan can effectively reduce the levels of Scr, BUN and Cys-C in patients with early diabetic nephropathy, reduce the quantification of 24h urine protein, reduce the clinical syndrome score of TCM, and improve clinical symptoms. The effect is exact.

參考文獻/References:

[1]王瑩瑩,王文革,鄧蓉蓉,等.甘肅省1828例腎活檢病理資料及流行病學特點[J].中華腎臟病雜志,2019,35(3):212-214. [2]中華醫學會糖尿病學分會.中國2型糖尿病防治指南(2017年版)[J].中華糖尿病雜志,2018,10(1):4-67. [3]Mogensen CE.Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes [J].New England Joumal of Medicine,1984,310(6):356-360. [4]周鑫,陸俊峰,溫泉.益氣補腎化瘀方治療早期糖尿病腎病臨床觀察[J].安徽中醫藥大學學報,2019,38(3):30-34. [5]吳仁凱,王杰,徐清喜.黃葵膠囊聯合纈沙坦治療糖尿病腎病臨床療效探討[J].中國生化藥物雜志,2017,37(6):236-237. [6]錢雅玉,朱玲,王世榮.二參益氣補腎膠囊治療糖尿病腎病辨證思路[J].中國民間療法,2017,25(8):63-64. [7]宋高峰,鄭義侯,孫惠力,等.2型糖尿病腎病患者不同分期中醫證候特點分析[J].江西中醫藥,2019,50(7):27-30. [8]徐愛華.黃芪注射液在糖尿病腎病治療中的應用效果及價值研究[J].實用中西醫結合臨床,2019,19(3):73-75. [9]易婷婷,栗萍,張明慧,等.黃芪對糖尿病腎病小鼠內質網應激中蛋白激酶R樣內質網激酶通路的影響[J].中國臨床藥理學雜志,2019,35(8):785-787. [10]傅亮,李玉杰,來媛媛,等.黃芪注射液聯合葛根素注射液對HK-2細胞TGF-β1/Smads及BMP-7/Smad5信號通路的影響[J].環球中醫藥,2019,12(3):343-347. [11]劉美霞,戚進,余伯陽.黨參藥理作用研究進展[J].海峽藥學,2018,30(11):36-37. [12]曾艷,賈正平,張汝學.地黃化學成分及藥理研究進展[J].中成藥,2006,28(4):609-611. [13]徐碩,姜文清,鄺詠梅,等.茯苓的化學成分及生物活性研究進展[J].西北藥學雜志,2016,31(3):327-329. [14]田婷,陳華,馮亞龍,等.澤瀉藥理與毒理作用的研究進展[J].中藥材,2014,37(11):2103-2108. [15]段煜,裴科,蔡皓,等.以黃芪-山茱萸治療糖尿病腎病為例探究藥對研究的新策略[J].中國中藥雜志,2016,41(21):3919-3926. [16]邵禮梅,許世偉.山藥化學成分及現代藥理研究進展[J].中醫藥學報,2017,45(2):125-127.

相似文獻/References:

[1]陳淑雯.腎衰寧聯合科素亞治療早期糖尿病腎病的臨床觀察[J].醫學信息,2018,(05):20.[doi:10.3969/j.issn.1006-1959.2018.05.007]
 CHEN Shu-wen.Clinical Observation on Early Diabetic Nephropathy Treated by Shenshuaining Combined with Kosu[J].Medical Information,2018,(22):20.[doi:10.3969/j.issn.1006-1959.2018.05.007]
[2]何麗杰.中西醫治療糖尿病腎病的臨床效果分析[J].醫學信息,2018,(10):149.[doi:10.3969/j.issn.1006-1959.2018.10.051]
 HE Li-jie.Clinical Effect Analysis of Diabetic Nephropathy Treated by Chinese and Western Medicine[J].Medical Information,2018,(22):149.[doi:10.3969/j.issn.1006-1959.2018.10.051]
[3]賀 偉,高 峰.24 h尿微量白蛋白、血清胱抑素C水平與血清肌酐、尿素水平在2型糖尿病腎病早期診斷的意義[J].醫學信息,2018,(11):151.[doi:10.3969/j.issn.1006-1959.2018.11.049]
 HE Wei,GAO Feng.The Significance of 24 h Urinary Microalbumin,Serum Cystatin C and Serum Creatinine and Urea Levels in the Early Diagnosis of Type 2 Diabetic Nephropathy[J].Medical Information,2018,(22):151.[doi:10.3969/j.issn.1006-1959.2018.11.049]
[4]黃秋菊.胱抑素C及脂蛋白α在早期糖尿病腎病診斷中的價值研究[J].醫學信息,2018,(14):57.[doi:10.3969/j.issn.1006-1959.2018.14.018]
 HUANG Qiu-ju.The Value of Cystatin C and Lipoprotein α in the Diagnosis of Early Diabetic Nephropathy[J].Medical Information,2018,(22):57.[doi:10.3969/j.issn.1006-1959.2018.14.018]
[5]陸新虹,溫玉潔,胡 欣,等.α-硫辛酸對2型糖尿病腎病患者 血清內脂素的影響研究[J].醫學信息,2018,(14):60.[doi:10.3969/j.issn.1006-1959.2018.14.019]
 LU Xin-hong,WEN Yu-jie,HU Xin,et al.Effect of α-lipoic Acid on Serum Visfatin in Patients with Type 2 Diabetic Nephropathy[J].Medical Information,2018,(22):60.[doi:10.3969/j.issn.1006-1959.2018.14.019]
[6]鄭小鵬,辛 華.糖尿病腎病研究進展[J].醫學信息,2018,(16):26.[doi:10.3969/j.issn.1006-1959.2018.16.008]
 ZHENG Xiao-peng,XIN Hua.Progress in the Study of Diabetic Nephropathy[J].Medical Information,2018,(22):26.[doi:10.3969/j.issn.1006-1959.2018.16.008]
[7]李志俊,王 利,王 浩.姜黃素改善糖尿病腎病的作用機制研究[J].醫學信息,2018,(24):35.[doi:10.3969/j.issn.1006-1959.2018.24.010]
 LI Zhi-jun,WANG Li,WANG Hao.Study on the Mechanism of Curcumin in Improving Diabetic Nephropathy[J].Medical Information,2018,(22):35.[doi:10.3969/j.issn.1006-1959.2018.24.010]
[8]肖學秀.益氣活血湯聯合西藥治療早期糖尿病腎病的臨床觀察[J].醫學信息,2019,(02):166.[doi:10.3969/j.issn.1006-1959.2019.02.051]
 XIAO Xue-xiu.Clinical Observation of Yiqi Huoxue Decoction Combined with Western Medicine in Treating Earlyn Diabetic Nephropathy[J].Medical Information,2019,(22):166.[doi:10.3969/j.issn.1006-1959.2019.02.051]
[9]張國艷,張佳田,隋洪玉.糖尿病腎病大鼠動物模型建立及INF-α干預機制研究[J].醫學信息,2019,(05):101.[doi:10.3969/j.issn.1006-1959.2019.05.030]
 ZHANG Guo-yan,ZHANG Jia-tian,SUI Hong-yu.Establishment of Animal Model of Diabetic Nephropathy Rats and Study of INF-α Intervention Mechanism[J].Medical Information,2019,(22):101.[doi:10.3969/j.issn.1006-1959.2019.05.030]
[10]吳怡琪,盧 文.皮膚AGEs熒光檢測對糖尿病腎病的臨床意義[J].醫學信息,2019,(06):101.[doi:10.3969/j.issn.1006-1959.2019.06.031]
 WU Yi-qi,LU Wen.Clinical Significance of Skin AGEs Fluorescence Detection in Diabetic Kidney Disease[J].Medical Information,2019,(22):101.[doi:10.3969/j.issn.1006-1959.2019.06.031]

更新日期/Last Update: 2019-11-15
中国足彩网竞彩